PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.

By F. Raal, Evan A. Stein, R. Dufour, T. Turner, F. Civeira, L. Burgess, G. Langslet, Russell S. Scott, Anders G. Olsson, D. Sullivan and 8 more. The Lancet, 2015

665 citations recorded by the source corpus.

Subfields: Cell Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/9a2956fc3a2d0bd19c2514cdf58eee978ee0651f